SCHEMBL3516637

SCHEMBL3516637

O=C(O)c1c(O)cc(Br)c2nccnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
CYP3A4 P08684 1/20 0.36
ACHE P22303 1/20 0.36
TTR P02766 1/20 0.35
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4A O75164 2/20 0.34
EGLN1 Q9GZT9 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
RAB9A P51151 1/20 0.34
HIF1AN Q9NWT6 1/20 0.34
KDM6B O15054 1/20 0.34
KDM6A O15550 1/20 0.34
TET3 O43151 1/20 0.34
KDM4B O94953 1/20 0.34
KDM5C P41229 1/20 0.34
KDM4D Q6B0I6 1/20 0.34
TET2 Q6N021 1/20 0.34
ALKBH5 Q6P6C2 1/20 0.34
TET1 Q8NFU7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520599 0.78 FTO (0.48) EGLN1FTOKDM2A
SCHEMBL3519951 0.73 BACE1 (0.47) KDM4ECYP3A4ALDH1A1KDM4AEGLN1
SCHEMBL3519604 0.71 KDM4E (0.45) KDM4ETTRALDH1A1SMN1; SMN2DHODH
SCHEMBL3766998 0.68 CA12 (0.43) KDM4EALDH1A1KDM4AEGLN1L3MBTL1
SCHEMBL18387384 0.67 TDP1 (0.57) KDM4ECYP3A4TTRALDH1A1SMN1; SMN2
SCHEMBL21818747 0.67 TTR (0.48) KDM4ETTRALDH1A1SMN1; SMN2KDM4A
SCHEMBL15523819 0.66 CA1 (0.50) KDM4ECYP3A4ACHETTRALDH1A1
SCHEMBL15524729 0.66 CYP3A4 (0.57) CYP3A4ACHETTRALDH1A1CA1
SCHEMBL25097311 0.65 KDM4E (0.46) KDM4ECYP3A4ALDH1A1SMN1; SMN2KDM4A
SCHEMBL30217795 0.65 KDM4E (0.46) KDM4ECYP3A4ALDH1A1SMN1; SMN2KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 KDM4E 176/4885CYP3A4 824/4885ACHE 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.